By Paolo Aloisi M.D., Francesco Martella Ph.D. (auth.), Mauro Bologna (eds.)
Biotargets of melanoma in present scientific Practice provides an up to date and reasoned evaluate of the present prestige of data about the significant melanoma forms with a unique specialise in the present biomarkers, genes concerned and the capability destiny ambitions of leading edge cures. the amount comprises for every significant melanoma style, a accomplished even supposing concise dialogue of epidemiology, affirmed and cutting edge biomarkers for analysis, and outlines of the correct genes for analysis and (individualized) treatment via biotarget-specific new molecular remedies, with the most recent details at the validation prestige of every novel biomarker. person chapters are devoted to the key melanoma kinds, plus a distinct bankruptcy on metastasis. the current debate on patentability of genetic details utilized to diagnostics and therapeutics of melanoma is usually discussed.
Read or Download Biotargets of Cancer in Current Clinical Practice PDF
Similar cancer books
Regardless of the world-wide force to extend wisdom of the dangers of smoking, lung melanoma continues to be a world challenge. A multidisciplinary staff process is now thought of the simplest solution to deal with lung melanoma. Imaging performs a important function during this multidisciplinary strategy; this can be mirrored within the current quantity.
Johns Hopkins sufferers' consultant to Lung melanoma is a concise, easy-to-follow “how to” consultant that places you at the route to wellbeing via explaining lung melanoma remedy from begin to end. It publications you thru the overpowering maze of remedy judgements, simplifies the advanced time table that lies forward, and plays the duty of placing jointly your plan of care in layman's phrases.
- Beyond miracles: living with cancer : inspirational and practical advice for patients and their families
- Camptothecins in Cancer Therapy (Cancer Drug Discovery and Development)
- Early Cancer of the Gastrointestinal Tract / Endoscopy, Pathology, and Treatment
- The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable--and How We Can Get There
- Cancer of the Skin: Expert Consult, 2nd Edition
Extra info for Biotargets of Cancer in Current Clinical Practice
43. Knobbe CB, Merlo A, Reifenberger G. Pten signaling in gliomas. Neuro Oncol. 2002;4(3):196–211. 44. Dey N, Crosswell HE, De P, et al. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008;68(6):1862–71. 45. Li Y, Guessous F, Kwon S, et al. PTEN has tumorpromoting properties in the setting of gain-of function p53 mutations. Cancer Res. 2008;68(6):1723–31. 46. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O’Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB.
4 months . Similarly, in another open-label, nonrandomized phase II clinical trial to determine the efﬁcacy of temsirolimus in patients with recurrent GBM, one patient remained progression free at 6 months, and of the patients assessable for response, two PR were observed, and 20 patients had SD. 7%), there was no evidence of an improved response to temsirolimus treatment in patients with recurrent GBM. Overall, temsirolimus treatment appears to be less effective than the standard Stupp regimen.
Proc Am Soc Clin Oncol. 2004;23:110. 69. Galanis E, et al. Phase II trial of temsirolimus (CCI779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23:5294–304. 70. Chang SM, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23:357–61. 71. Cloughesy TF, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Biotargets of Cancer in Current Clinical Practice by Paolo Aloisi M.D., Francesco Martella Ph.D. (auth.), Mauro Bologna (eds.)